Animal welfare groups say ECHA’s approach to animal testing proposals under REACH has changed negligibly since a European ombudsman solution rendered in September 2015. ECHA is now requiring registrants to account for alternative considerations, but says it has no power to reject testing proposals on the grounds that such considerations are inadequate, a position the groups may challenge in the courts.
Cruelty Free International expects a response by the end of March from the European ombudsman regarding the European Chemical Agency’s alleged maladministration of REACH’s “last resort” principle, a dispute that could move next to the EU courts.
According to CFI and other members of the European Coalition to End Animal Experiments, unnecessary animal testing continues to be...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
